Dear Editor,

We would like to describe a case of EMS presenting with a clinical picture of skin rashes, pneumonitis, myalgias, and cognitive impairment with plaque-like T2 frontal white matter hyperintensities on magnetic resonance imaging of brain to better acquaint clinicians and radiologists with this rare entity.

The eosinophilia-myalgia syndrome (EMS) is a multisystem disorder falling on the spectrum of eosinophil-mediated ailments. First identified in 1989, approximately 1500 cases have been reported so far worldwide and almost twice that number failed to meet the CDC diagnostic criteria.10 Previously associated with ingestion of therapeutic L-tryptophan, EMS has now been identified in the absence of such history. An increase in eosinophil count, which forms the key component of the host immune system can result in cytotoxic tissue damage associated with release of granulocytes which can present as a variety of clinical manifestations ranging from skin abnormalities (Rashes, fasciitis, sclerosis, thickening of deep fascia), pulmonary disorders (Pneumonitis, vasculitis), hepatic dysfunction to systemic manifestations like fatigue, arthralgias, edema and sensory/motor abnormalities and cognitive impairment.

A 65-year-old woman presented to us with complaints of fatigue with skin rashes, undocumented intermittent fever, forgetfulness, and gradually progressive shortness of breath since 3 months. A complete hemogram, liver, and kidney function tests, and CECT (Contrast Enhanced computed tomography) chest were performed. Hemogram revealed normocytic normochromic anemia with total leukocyte count (~8400) with differential leukocyte count showing elevated lymphocytes and severe eosinophilia ~47% with
an absolute eosinophil count ~3950 cells/mm\(^3\). Liver and kidney function tests were within normal range. CECT chest showed presence of B/L pleural effusion with fluid tracking along the fissures with minimal pericardial effusion as shown in [Figure 1a]. Analysis of the pleural fluid revealed benign eosinophilic effusion with DLC: N (20%), M (6%), E (68%), L (6%). Pleural fluid ADA was within normal range. Pleural fluid cytology showed absence of atypical/malignant cells. Echocardiography revealed normal ejection fraction (60%) and no vegetations/clots. Electrocardiography showed normal sinus rhythm. Dermatological consultation showed chronic urticaria. Inflammatory markers including ESR (110 mm/h) and s. ferritin (425) were raised. Serological tests for trichinosis, scrub typhus, brucellosis and leptospirosis came back negative. The patient also complained of generalized body weakness with myalgias. Nerve conduction study revealed mixed neuropathy (axonal > demyelination) B/L median, ulnar, common peroneal, tibial nerves. Bone marrow imprint smear revealed severe eosinophilia with DLC showing 70% eosinophils, however, no immature/dysplastic forms of eosinophils were seen in the smear. Other tests including Anti-nuclear, anti-double-stranded DNA, anti-neutrophil/ cytoplasmic, and anti-CCP antibodies were negative or normal. The patient was a known hypertensive for which she was on medication. Other than that, the patient denied a history of any drug intake, ayurvedic or alternative medication. Our patient denied a history of consumption of L-tryptophan-containing dietary supplements. Neurological and psychiatric consultation revealed impaired working and semantic memory and impaired sustained attention for which MRI brain was performed which revealed the presence of plaque-like T2 FLAIR hyperintensities in B/L frontal (Left > Right) periventricular/deep white matter as shown in [Figure 1b].

The diagnostic criteria for Eosinophilia myalgia syndrome (EMS) described by Philip A. Hertzman et al.\(^3\) includes fulfillment of either pattern 1 or pattern 2 and absence of exclusions as follows:

Pattern 1: Presence of documented illness of relatively discrete or abrupt onset of all three manifestations including eosinophilia, myalgia, and at least one rash, edema, pulmonary involvement or neuropathy within 6 months in absence of exclusions.

Pattern 2: Presence of illness with/without documented early episode accompanied by one of the following within 24 months of illness onset: 1. Fasciitis, neuropathy, myalgia or muscle cramps; or 2. Any 3 or more of fasciitis, myopathy, neuropathy or eosinophilia (within 6 months of onset).

Exclusions: EMS is not to be diagnosed in presence of trichinosis, vasculitis or any other documented infectious, allergic, neoplastic, connective tissue, or other diseases that could adequately explain the clinical manifestations.

Neurological imaging in EMS shows evidence of white matter injury in the form of T2 FLAIR (Fluid attenuation inversion recovery) hyperintensities predominantly involving the frontal lobe periventricular/deep white matter showing no diffusion restriction, susceptibility changes, mass effect or post-contrast enhancement\(^3\) similar to our patient [Figure 1b]. Studies conducted by Armstrong et al.\(^3\) revealed white matter hyperintensities on MRI in the frontal lobe in EMS patients with no other neurological diseases such as hypertension or diabetes which could account for these lesions like in our case.

Based on the above findings provisional diagnosis of EMS was kept and the patient was started on oral corticosteroids at 1 mg/kg body weight. After 4 weeks response assessment showed a dramatic response in the form of fall in peripheral eosinophilia (3.7% DLC), fall in ESR (32 mm/h), and complete resolution of pleural and pericardial effusion on follow up chest CT as shown in [Figure 1c]. The patient showed improvement in cognition with improved working memory.

Other than eosinophil-derived toxicity, autoimmune responses including cellular and humoral immunity have been shown to play a role in the pathogenesis of this rare multisystem disease. Although our patient tested negative for the presence of anti-nuclear antibodies (ANA) which are found in up to 50% of patients of EMS,\(^4\) elevated lymphocytes as a result of cellular immune response was seen in our patient.
The presence of peripheral eosinophilia with neurological symptoms should raise the suspicion of eosinophilic meningitis, eosinophilia-myalgia syndrome, and hyper eosinophilic syndrome in that order. Eosinophilic meningitis may be idiopathic or may occur as a reaction to helminthic infestation elsewhere in the body. Eosinophilic myalgia syndrome will present as extensive body ache and multigorgan system involvement. Hyper eosinophilic syndrome rarely results in CNS involvement. Imaging may help differentiate these entities and arrive at the correct diagnosis. Eosinophilic meningitis will show leptomeningeal enhancement with edema in the underlying brain parenchyma. EMS shows confluent frontal white matter hyperintensities as seen in our case. Hyper eosinophilic syndrome shows enhancing open ring active demyelination with white matter hyperintensities.

Emotional distress including depression was found to be significantly higher in patients with EMS. Our patient showed improvement in working memory and attention span with treatment.

Studies have shown that 100% of the patients of EMS showed fatigue and myalgias as a symptom. Our patient complained of generalized body weakness that was severe enough to impair her day-to-day functions with myalgias. Myalgias showed a significant response to treatment enabling the patient to carry out daily activities. Perimyositis appears to be the histopathological process behind myalgias in EMS with infiltrating inflammatory cells seen at perivascular, perimysial, and fascial locations.

Even though the clinical, pathological, and radiological findings in patients of EMS have been well demonstrated, the etiopathogenesis of this disease is yet unknown. Acquainting treating clinicians and radiologists with this disease can help in preventing delayed diagnosis, improve our understanding of the disease, and possibly aid in understanding the cure.

Financial support and sponsorship
Nil.

Conflicts of interest
There are no conflicts of interest.

Marisa Yadav, Suresh Kumar, Anupam Jhobta, Sushma Makhaik
Department of Radiodiagnosis and Imaging, IGMC Shimla, Himachal Pradesh, India

Address for correspondence: Dr. Suresh Kumar, Department of Radiodiagnosis and Imaging IGMC Shimla - 171 001, Himachal Pradesh, India.
E-mail: thakursuresh67@yahoo.co.in

References
1. Woolf AD. Eosinophilia-myalgia syndrome—United States, 1989. History of Modern Clinical Toxicology, 2022:71-83.
2. Hertzman PA, Clauw DJ, Duffy J, Medsger TA Jr, Feinstein AR. Rigorous new approach to constructing a gold standard for validating new diagnostic criteria, as exemplified by the eosinophilia-myalgia syndrome. Arch Intern Med 2001;161:2301-6.
3. Armstrong C, Lewis T, D’Esposito M, Freundlich B. Eosinophilia-myalgia syndrome: Selective cognitive impairment, longitudinal effects, and neuroimaging findings. J Neurol Neurosurg Psychiatry 1997;63:633-41.
4. Varga J, Heiman-Patterson TD, Emery DL, Griffin R, Lally EV, Uitto JJ, et al. Clinical spectrum of the systemic manifestations of the eosinophilia-myalgia syndrome. Semin Arthritis Rheum 1990;19:313-28.
5. Kaufman LD, Seidman RJ, Gruber BL. L-tryptophan-associated eosinophilic perimyositis, neuritis, and fasciitis. A clinicopathologic and laboratory study of 25 patients. Medicine 1990;69:187-99.
6. Martin RW, Duffy J, Engel AG, Lie JT, Bowles CA, Moyer TP, et al. The clinical spectrum of the eosinophilia-myalgia syndrome associated with L-tryptophan ingestion: Clinical features in 20 patients and aspects of pathophysiology. Ann Intern Med 1990;113:124-34.
7. Prick JJ. L-tryptophan and the eosinophilia-myalgia syndrome. Ned Tijdschr Geneesk 1990;134:1516-7.
8. Heiman-Patterson TD, Bird SJ, Parry GJ, Varga J, Shy ME, Culligan NW, et al. Peripheral neuropathy associated with eosinophilia-myalgia syndrome. Ann Neurol 1990;28:522-8.

Submitted: 22-Sep-2021 Revised: 17-Dec-2021 Accepted: 18-Dec-2021
Published: 25-Mar-2022

This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

DOI: 10.4103/aian.aian_844_21